Reducing inflammation and improving metabolic health in people living with HIV
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV
This study is looking at whether a new drug can help reduce inflammation and improve health for people living with HIV by targeting certain receptors, and it will involve participants taking either the drug or a placebo for 24 weeks to see how it affects their heart and metabolism.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10918077 on NIH RePORTER |
What this research studies
This research investigates how targeting specific receptors (CCR2 and CCR5) can help reduce inflammation and improve metabolic health in individuals living with HIV. The study will involve a multicenter, placebo-controlled, double-blind trial where participants will receive either the drug cenicriviroc or a placebo over 24 weeks. By examining the effects on arterial inflammation and insulin resistance, the research aims to understand how these treatments can enhance cardiovascular health and metabolic function in this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults living with HIV who are on stable antiretroviral therapy and have an increased risk of cardiovascular disease.
Not a fit: Patients who are not living with HIV or those who do not have increased cardiovascular disease risk may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cardiovascular health and metabolic outcomes for people living with HIV.
How similar studies have performed: Other research has shown promise in targeting similar pathways for reducing inflammation and improving health outcomes in HIV populations, suggesting a potential for success in this approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lo, Janet — Massachusetts General Hospital
- Study coordinator: Lo, Janet
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.